Systemic Protein Delivery via Inhalable Liposomes : Formulation and Pharmacokinetics
The enormous and thin alveolar epithelium is an attractive site for systemic protein delivery. Considering the excellent biocompatibility of phospholipids with endogenous pulmonary surfactant, we engineered dimyristoylphosphatidylcholine (DMPC)-based liposomes for pulmonary administration, using Cy5.5-labeled bovine serum albumin (BSA-Cy5.5) as a model protein payload. The level of cholesterol (Chol) and surface modification with PEG in inhalable liposomes were optimized iteratively based on the encapsulation efficiency, the release kinetics in the simulated lung fluid, and the uptake in murine RAW 264.7 macrophages. The plasma pharmacokinetics of BSA-Cy5.5-encapsulated liposomes with the composition of DMPC/Chol/PEG at 85:10:5 (molar ratio) was studied in mice following intratracheal aerosolization, in comparison with that of free BSA-Cy5.5 solution. The biodisposition of BSA-Cy5.5 was continuously monitored using whole-body near-infrared (NIR) fluorescence imaging for 10 days. We found that the systemic bioavailability of BSA-Cy5.5 from inhaled liposomes was 22%, which was notably higher than that of inhaled free BSA-Cy5.5. The mean residence time of BSA-Cy5.5 was markedly prolonged in mice administered intratracheally with liposomal BSA-Cy5.5, which is in agreement with the NIR imaging results. Our work demonstrates the great promise of inhalable DMPC-based liposomes to achieve non-invasive systemic protein delivery.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Pharmaceutics - 15(2023), 7 vom: 14. Juli |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ponkshe, Pranav [VerfasserIn] |
---|
Links: |
---|
Themen: |
DMPC |
---|
Anmerkungen: |
Date Revised 01.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/pharmaceutics15071951 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360140084 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM360140084 | ||
003 | DE-627 | ||
005 | 20231226082357.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/pharmaceutics15071951 |2 doi | |
028 | 5 | 2 | |a pubmed24n1200.xml |
035 | |a (DE-627)NLM360140084 | ||
035 | |a (NLM)37514138 | ||
035 | |a (PII)1951 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ponkshe, Pranav |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systemic Protein Delivery via Inhalable Liposomes |b Formulation and Pharmacokinetics |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.08.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a The enormous and thin alveolar epithelium is an attractive site for systemic protein delivery. Considering the excellent biocompatibility of phospholipids with endogenous pulmonary surfactant, we engineered dimyristoylphosphatidylcholine (DMPC)-based liposomes for pulmonary administration, using Cy5.5-labeled bovine serum albumin (BSA-Cy5.5) as a model protein payload. The level of cholesterol (Chol) and surface modification with PEG in inhalable liposomes were optimized iteratively based on the encapsulation efficiency, the release kinetics in the simulated lung fluid, and the uptake in murine RAW 264.7 macrophages. The plasma pharmacokinetics of BSA-Cy5.5-encapsulated liposomes with the composition of DMPC/Chol/PEG at 85:10:5 (molar ratio) was studied in mice following intratracheal aerosolization, in comparison with that of free BSA-Cy5.5 solution. The biodisposition of BSA-Cy5.5 was continuously monitored using whole-body near-infrared (NIR) fluorescence imaging for 10 days. We found that the systemic bioavailability of BSA-Cy5.5 from inhaled liposomes was 22%, which was notably higher than that of inhaled free BSA-Cy5.5. The mean residence time of BSA-Cy5.5 was markedly prolonged in mice administered intratracheally with liposomal BSA-Cy5.5, which is in agreement with the NIR imaging results. Our work demonstrates the great promise of inhalable DMPC-based liposomes to achieve non-invasive systemic protein delivery | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a DMPC | |
650 | 4 | |a inhalable liposome | |
650 | 4 | |a pharmacokinetics | |
650 | 4 | |a systemic protein delivery | |
700 | 1 | |a Wang, Yingzhe |e verfasserin |4 aut | |
700 | 1 | |a Tan, Chalet |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d 2010 |g 15(2023), 7 vom: 14. Juli |w (DE-627)NLM204303303 |x 1999-4923 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2023 |g number:7 |g day:14 |g month:07 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmaceutics15071951 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2023 |e 7 |b 14 |c 07 |